Department of Cardiology, Herlev Gentofte University Hospital, DK.
Faculty of Health and Medical Science, University of Copenhagen, DK.
Glob Heart. 2020 Mar 25;15(1):25. doi: 10.5334/gh.776.
This study evaluated the associations between the natriuretic peptide activity and the neurohormonal response in non-obese and obese outpatients with and without heart failure (HF).
Obesity-related HF may be a distinct subtype of HF. Obesity is associated with lower plasma concentrations of natriuretic peptides. The associations between obesity and neurohormonal activation estimated by mid-regional pro-adrenomedullin (MR-proADM) and copeptin in patients with HF is not elucidated.
This prospective cohort-study included 392 outpatients ≥60years, plus ≥1 risk-factor(-s) for HF (hypertension, ischemic heart disease, atrial fibrillation, diabetes, chronic kidney disease), and without known HF. Patients were categorized 'non-obese' BMI = 18.5-29.9 kg/m (n = 273) and 'obese' BMI ≥ 30 kg/m (n = 119). The diagnosis of HF required signs, symptoms, and abnormal echocardiography. NT-proBNP, MR-proANP, MR-proADM, and copeptin were analyzed.
Obese patients were younger, had a higher prevalence of diabetes and chronic kidney disease, but a lower prevalence of atrial fibrillation. A total of 39 (14.3%) non-obese and 26 (21.8%) obese patients were diagnosed with HF. In obese patients, HF was not associated with higher plasma concentrations of NT-proBNP (Estimate: 0.063; 95%CI: -0.037-1.300; P = 0.064), MR-proANP (Estimate: 0.207; 95%CI: -0.101-0.515; P = 0.187), MR-proADM (Estimate: 0.112; 95%CI: -0.047-0.271; P = 0.168), or copeptin (Estimate: 0.093; 95%CI: -0.333-0.518; P = 0.669). Additionally, obese patients with HF had lower plasma concentrations of NT-proBNP (Estimate: -0.998; 95%CI: -1.778-0.218; P = 0.012), and MR-proANP (Estimate: -0.488; 95%CI: -0.845-0.132; P = 0.007) compared to non-obese patients with HF, whereas plasma concentrations of MR-proADM (Estimate: 0.066; 95%CI: -0.119-0.250; P = 0.484) and copeptin (Estimate: 0.140; 95%CI: -0.354-0.633; P = 0.578) were comparable.
Patients with obesity-related HF have natriuretic peptide deficiency and lack of increased plasma concentrations of MR-proADM and copeptin suggesting that patients with obesity-related HF have a blunted overall neurohormonal activity.
本研究评估了利钠肽活性与非肥胖和肥胖伴有或不伴有心力衰竭(HF)的门诊患者神经激素反应之间的关系。
肥胖相关 HF 可能是 HF 的一个独特亚型。肥胖与较低的血浆利钠肽浓度相关。肥胖患者中由 mid-regional pro-adrenomedullin (MR-proADM) 和 copeptin 估计的神经激素激活与 HF 患者之间的关系尚未阐明。
本前瞻性队列研究纳入了 392 名年龄≥60 岁且伴有≥1 个 HF 风险因素(高血压、缺血性心脏病、心房颤动、糖尿病、慢性肾脏病)的门诊患者,但无已知 HF。患者分为“非肥胖”BMI = 18.5-29.9 kg/m(n = 273)和“肥胖”BMI ≥ 30 kg/m(n = 119)。HF 的诊断需要有体征、症状和异常超声心动图。分析 NT-proBNP、MR-proANP、MR-proADM 和 copeptin。
肥胖患者更年轻,糖尿病和慢性肾脏病的患病率更高,但心房颤动的患病率较低。共有 39 名(14.3%)非肥胖患者和 26 名(21.8%)肥胖患者被诊断为 HF。在肥胖患者中,HF 与较高的 NT-proBNP 血浆浓度无关(估计值:0.063;95%CI:-0.037-1.300;P = 0.064)、MR-proANP(估计值:0.207;95%CI:-0.101-0.515;P = 0.187)、MR-proADM(估计值:0.112;95%CI:-0.047-0.271;P = 0.168)或 copeptin(估计值:0.093;95%CI:-0.333-0.518;P = 0.669)。此外,肥胖伴有 HF 的患者 NT-proBNP(估计值:-0.998;95%CI:-1.778-0.218;P = 0.012)和 MR-proANP(估计值:-0.488;95%CI:-0.845-0.132;P = 0.007)的血浆浓度较低,而非肥胖伴有 HF 的患者则较低,而 MR-proADM(估计值:0.066;95%CI:-0.119-0.250;P = 0.484)和 copeptin(估计值:0.140;95%CI:-0.354-0.633;P = 0.578)的血浆浓度则相当。
肥胖相关 HF 患者存在利钠肽缺乏,且缺乏 MR-proADM 和 copeptin 血浆浓度升高,这表明肥胖相关 HF 患者的整体神经激素活性减弱。